<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">RSX</journal-id>
<journal-id journal-id-type="hwp">sprsx</journal-id>
<journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id>
<journal-title>Reproductive Sciences</journal-title>
<issn pub-type="ppub">1933-7191</issn>
<issn pub-type="epub">1933-7205</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1933719111424438</article-id>
<article-id pub-id-type="publisher-id">10.1177_1933719111424438</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sertraline Alters Multidrug Resistance Phosphoglycoprotein Activity in the Mouse Placenta and Fetal Blood–Brain Barrier</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bhuiyan</surname>
<given-names>Manzerul</given-names>
</name>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="aff1-1933719111424438">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Petropoulos</surname>
<given-names>Sophie</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111424438">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gibb</surname>
<given-names>William</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-1933719111424438">2</xref>
<xref ref-type="aff" rid="aff3-1933719111424438">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Matthews</surname>
<given-names>Stephen G.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111424438">1</xref>
<xref ref-type="aff" rid="aff4-1933719111424438">4</xref>
<xref ref-type="corresp" rid="corresp1-1933719111424438"/>
</contrib>
</contrib-group>
<aff id="aff1-1933719111424438">
<label>1</label>Department of Physiology, University of Toronto, Toronto , Canada</aff>
<aff id="aff2-1933719111424438">
<label>2</label>Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Canada</aff>
<aff id="aff3-1933719111424438">
<label>3</label>Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada</aff>
<aff id="aff4-1933719111424438">
<label>4</label>Department of Obstetrics and Gynecology, Faculty of Medicine, University of Toronto, Toronto, Canada</aff>
<author-notes>
<corresp id="corresp1-1933719111424438">Stephen G. Matthews, Department of Physiology, Faculty of Medicine, University of Toronto, Medical Sciences Building, 1 King’s College Circle, Toronto, Ontario M5S1A8, Canada Email: <email>stephen.matthews@utoronto.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>4</issue>
<fpage>407</fpage>
<lpage>415</lpage>
<permissions>
<copyright-statement>© Society for Gynecologic Investigation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder>
</permissions>
<abstract>
<p>Phosphoglycoprotein (P-gp) is highly expressed in the placental syncytiotrophoblast and prevents xenobiotics from entering the fetus. In tumor cells, P-gp-mediated substrate efflux is inhibited by selective serotonin reuptake inhibitors (SSRIs). However, nothing is known regarding the effects of SSRIs on P-gp function in the placenta or fetal tissues. We hypothesized that the SSRI sertraline would decrease P-gp-mediated drug efflux at the placenta and fetal blood–brain barrier (BBB)—increasing P-gp substrate transfer from the mother to the fetus and fetal brain. In contrast to our hypothesis, this study presents the novel findings that sertraline (4 hours exposure) increases placental P-gp-mediated efflux (<italic>P </italic>&lt; .001), resulting in decreased drug transfer to the fetus. Meanwhile, sertraline decreases fetal (<italic>P </italic>&lt; .001) and maternal (<italic>P </italic>&lt; .05) BBB P-gp-mediated efflux, resulting in increased drug transfer into the fetal and maternal brain from the circulation. This suggests that P-gp regulation by sertraline is tissue specific. These findings have important clinical implications with respect to fetal protection during maternal drug therapy in pregnancy.</p>
</abstract>
<kwd-group>
<kwd>placenta</kwd>
<kwd>brain</kwd>
<kwd>multidrug resistance phosphoglycoprotein</kwd>
<kwd>sertraline</kwd>
<kwd>[<sup>3</sup>H]digoxin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1933719111424438">
<title>Introduction</title>
<p>Multidrug resistance phosphoglycoprotein (P-gp) is a member of the adenosine triphosphate (ATP)-binding cassette (ABC) superfamily. In humans, P-gp is encoded by the <italic>ABCB1</italic> gene and was first discovered in tumor cells resistant to chemotherapeutic agents.<sup>
<xref ref-type="bibr" rid="bibr1-1933719111424438">1</xref>
</sup> In rats and mice, P-gp is encoded by the <italic>Abcb1a</italic> and <italic>Abcb1b</italic> genes as a result of gene duplication, and their combined distribution resembles that of the human <italic>ABCB1</italic> gene.<sup>
<xref ref-type="bibr" rid="bibr2-1933719111424438">2</xref>
<xref ref-type="bibr" rid="bibr3-1933719111424438"/>–<xref ref-type="bibr" rid="bibr4-1933719111424438">4</xref>
</sup> Since their discovery in cancer cells, the <italic>Abcb1</italic> genes and P-gp have been identified in normal tissues including liver, lungs, kidney, and intestinal epithelium as well as various barrier sites such as the blood–brain barrier (BBB), blood–testes barrier, and blood–placental barrier.<sup>
<xref ref-type="bibr" rid="bibr5-1933719111424438">5</xref>
<xref ref-type="bibr" rid="bibr6-1933719111424438"/>
<xref ref-type="bibr" rid="bibr7-1933719111424438"/>
<xref ref-type="bibr" rid="bibr8-1933719111424438"/>–<xref ref-type="bibr" rid="bibr9-1933719111424438">9</xref>
</sup> In these barrier tissues, P-gp functions to limit substrate transfer by extruding them back into circulation. The P-gp substrates include pesticides/herbicides, cardiac glycosides, natural and synthetic steroids, and antiviral and anticancer drugs.<sup>
<xref ref-type="bibr" rid="bibr10-1933719111424438">10</xref>
<xref ref-type="bibr" rid="bibr11-1933719111424438"/>
<xref ref-type="bibr" rid="bibr12-1933719111424438"/>
<xref ref-type="bibr" rid="bibr13-1933719111424438"/>
<xref ref-type="bibr" rid="bibr14-1933719111424438"/>
<xref ref-type="bibr" rid="bibr15-1933719111424438"/>–<xref ref-type="bibr" rid="bibr16-1933719111424438">16</xref>
</sup>
</p>
<p>Given the effectiveness of P-gp in excluding substrates from cells and in preventing transfer of substrates across blood barriers, there has been much interest in identifying factors that can effectively modulate P-gp-mediated substrate efflux. The P-gp inhibitors have been used to increase the intracellular accumulation of therapeutic drugs such as antiviral and anticancer drugs.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111424438">14</xref>
</sup> More recently, the selective serotonin reuptake inhibitors (SSRIs) were identified as a new class of P-gp inhibitors.<sup>
<xref ref-type="bibr" rid="bibr17-1933719111424438">17</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr18-1933719111424438">18</xref>
</sup> In the P-gp-expressing human HCT-15 cell line, fluoxetine increased intracellular accumulation of the anticancer drug doxorubicin, suggesting the inhibition of P-gp-mediated extrusion.<sup>
<xref ref-type="bibr" rid="bibr19-1933719111424438">19</xref>
</sup> In mice, doxorubicin treatment combined with fluoxetine significantly decreased tumor progression compared with doxorubicin treatment alone.<sup>
<xref ref-type="bibr" rid="bibr19-1933719111424438">19</xref>
</sup> This suggested that fluoxetine reduced P-gp-mediated efflux of doxorubicin from tumor cells, thereby increasing the therapeutic effect of the anticancer drug. Weiss and colleagues determined the effects of various SSRIs on P-gp function in L-Multidrug Resistance (L-MDR1) cells and primary cultures of porcine brain capillary endothelial cells and found that sertraline, desmethylsertraline, and paroxetine to be the most potent P-gp inhibitors.<sup>
<xref ref-type="bibr" rid="bibr17-1933719111424438">17</xref>
</sup>
</p>
<p>At the blood–placental barrier, P-gp protects the fetus by limiting the passage of xenobiotics in maternal circulation across the syncytiotrophoblast. The prevalence of mood disorders during pregnancy is estimated to be 10% to 15%, and many of these women are prescribed SSRIs.<sup>
<xref ref-type="bibr" rid="bibr20-1933719111424438">20</xref>
</sup> Therefore, it is critical to determine how SSRIs affect the placental barrier and fetal BBB and how they could influence fetal exposure of maternal drugs. If SSRIs inhibit placental P-gp, then this would increase fetal exposure to various xenobiotics. At the same time, this also introduces the possibility of a novel approach to drug treatment of the fetus. Specifically, one could theoretically treat fetal conditions by administering much lower quantities of drug thereby decreasing maternal side effects. The purpose of the present study was to determine the acute effects of the SSRI sertraline on P-gp function in the placenta and at the fetal blood–brain barrier.</p>
<p>We hypothesized that (1) sertraline would inhibit P-gp-mediated substrate efflux at the placenta, resulting in increased accumulation of P-gp substrate in the fetus, (2) sertraline would inhibit P-gp-mediated substrate efflux at the fetal blood–brain barrier, resulting in increased substrate accumulation in the fetal brain, and (3) these effects would be time and dose dependent.</p>
</sec>
<sec id="section2-1933719111424438">
<title>Materials and Methods</title>
<sec id="section3-1933719111424438">
<title>Animals</title>
<p>Female FVB mice (Charles River, Germantown, New York) were bred as we have described previously.<sup>
<xref ref-type="bibr" rid="bibr21-1933719111424438">21</xref>
</sup> Briefly, the appearance of a vaginal plug marked the onset of pregnancy and was designated as embryonic day (E) 0.5 (average gestation period: &lt;19.5 days). These studies were conducted using protocols approved by the Animal Care Committee at the University of Toronto and in accordance with the Canadian Council for Animal Care.</p>
</sec>
<sec id="section4-1933719111424438">
<title>In Vivo Distribution of [<sup>3</sup>H]Digoxin</title>
<p>At E15.5, pregnant FVB mice were injected (intravenously [IV]) with sertraline (1 mg/kg [n = 17] or 10 mg/kg [n = 17]) or vehicle (saline; n = 16) simultaneously with [<sup>3</sup>H]digoxin (1 μCi/dam). We previously demonstrated that expression of placental P-gp peaks at E12.5 and progressively declines toward term, and this is mirrored by changes in the activity of P-gp .<sup>
<xref ref-type="bibr" rid="bibr7-1933719111424438">7</xref>
</sup> In the fetal brain, we have previously demonstrated expression of <italic>Abcb1a </italic>messenger RNA on E15.5 and a progressive increase with advancing gestation.<sup>
<xref ref-type="bibr" rid="bibr22-1933719111424438">22</xref>
</sup> We chose E15.5 because P-gp is abundant in both the placenta and the fetal brain at this stage of gestation.<sup>
<xref ref-type="bibr" rid="bibr7-1933719111424438">7</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr22-1933719111424438">22</xref>
</sup> Sertraline was selected because it has been shown to produce the most potent inhibitory effects on P-gp-mediated substrate efflux in L-MDR1 cells and endothelial cells derived from adult brain microvessels.<sup>
<xref ref-type="bibr" rid="bibr17-1933719111424438">17</xref>
</sup> Experiments were undertaken with doses of 1 and 10 mg/kg. The lower dose is similar to that is used clinically to manage depression.<sup>
<xref ref-type="bibr" rid="bibr23-1933719111424438">23</xref>
</sup> Digoxin is the gold standard pharmacological marker for assessing P-gp-mediated substrate efflux.<sup>
<xref ref-type="bibr" rid="bibr13-1933719111424438">13</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr24-1933719111424438">24</xref>,<xref ref-type="bibr" rid="bibr25-1933719111424438">25</xref>
</sup> Studies using [<sup>3</sup>H]digoxin as an in vivo marker of P-gp-mediated substrate efflux have assessed the tissue distribution of [<sup>3</sup>H]digoxin in mice up to 240 minutes after (IV) injection.<sup>
<xref ref-type="bibr" rid="bibr13-1933719111424438">13</xref>
</sup> The dose administered has been previously used to assess transplacental transfer and transfer into the fetal brain in the mouse.<sup>
<xref ref-type="bibr" rid="bibr21-1933719111424438">21</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr22-1933719111424438">22</xref>
</sup> In the present study, animals were anesthesized with isofluorane and euthanized 5 minutes (n = 5-6 per group), 60 minutes (n = 5-6 per group), or 240 minutes (n = 5-6 per group) after injection. Litters were collected: (1) half of the fetuses from each litter were collected as fetal units, where fetal membranes containing amniotic fluid were left intact in order to assess total transplacental transfer and (2) brains were removed from the other half of the fetuses in order to assess [<sup>3</sup>H]digoxin transfer from the fetal body into the brain, as we have described previously.<sup>
<xref ref-type="bibr" rid="bibr21-1933719111424438">21</xref>
</sup> Maternal blood and maternal brains were also collected. Maternal blood (heparinized) was centrifuged and plasma was isolated. Fetal units, fetal bodies (from fetuses where brains were removed), fetal brains, and maternal brains were processed and analyzed as we have described previously.<sup>
<xref ref-type="bibr" rid="bibr21-1933719111424438">21</xref>
</sup> Briefly tissue was homogenized, and tissue homogenate (200 μL) and maternal plasma (100 μL) was solubilized in SOLVABLE (PerkinElmer, Waltham, Massachusetts). Hydrogen peroxide (100 uL; 30%) was added to optimize counting efficiency. Scintillation fluid (10 mL; Ultima-Gold; PerkinElmer) was added and radioactivity disintegrations per minute (DPM) is determined using a Tri-Carb Beta-Counter (PerkinElmer). To determine net transplacental transfer (ie, “drug ratio”) for each mother, the DPM value for each fetal unit was divided by the DPM value of maternal plasma. Drug ratios were averaged per litter and used for statistical analysis. In order to determine the drug distribution into the brain, the fetal brain to fetal body drug ratio and the maternal brain to maternal plasma drug ratio were also calculated. Fetal BBB P-gp substrate-mediated efflux was defined as the fetal brain to fetal body drug ratio instead of the fetal brain to fetal plasma ratio as it was not possible to collect sufficient fetal plasma.</p>
</sec>
<sec id="section5-1933719111424438">
<title>Passive Diffusion of [<sup>14</sup>C]Mannitol</title>
<p>[<sup>14</sup>C]Mannitol has been previously used to assess passive permeability at the placenta.<sup>
<xref ref-type="bibr" rid="bibr26-1933719111424438">26</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr27-1933719111424438">27</xref>
</sup> This was carried out in order to determine whether any effect of sertraline could be attributed to alterations in passive permeability at the placenta. At E15.5, pregnant FVB mice were injected (IV) with sertraline (10 mg/kg; n = 3) or vehicle (n = 3). After 236 minutes of this injection, animals were injected (IV) with [<sup>14</sup>C]mannitol (1.75 μCi/dam) and euthanized 4 minutes after injection, as described previously.<sup>
<xref ref-type="bibr" rid="bibr28-1933719111424438">28</xref>
</sup> Tissues were collected and drug ratios were assessed as described above.</p>
</sec>
<sec id="section6-1933719111424438">
<title>Sex Determination</title>
<p>DNA was extracted from fetal tails and fetal homogenate in order to determine the sex of the fetuses.<sup>
<xref ref-type="bibr" rid="bibr22-1933719111424438">22</xref>
</sup> Quantitative polymerase chain reaction (PCR) was performed to amplify Sry forward: 5′-GAGAGCATGGAGGGCCATG-3′ and Sry reverse: 5′-ATGCCACTCCTCTGTGACAC-3′ primers<sup>
<xref ref-type="bibr" rid="bibr29-1933719111424438">29</xref>
</sup> according to manufacturer’s guidelines (Sigma REDExtract-N-AMP Tissue PCR Kit (XNAT), Sigma Chemical Co, St Louis, Missouri). Amplification product was detected by 1% gel electrophoresis.</p>
</sec>
<sec id="section7-1933719111424438">
<title>Statistical Analysis</title>
<p>For each dam, ratio values derived for individual fetal units and fetal brains were averaged to provide a litter mean and to prevent litter bias. Group data are presented as mean ± standard error of the mean and were statistically analyzed using 2-way analysis of variance followed by the Bonferroni method of post hoc comparison. Differences in [<sup>14</sup>C]mannitol transport between vehicle and treatment groups were determined using unpaired Student <italic>t</italic> test using Prism (GraphPad Software Inc, San Diego, California). Significance was set at <italic>P </italic>&lt; .05. There was no significant effect of sex on P-gp-mediated substrate efflux or any interaction between sex and sertraline treatment. As a result, data from male and female fetuses were combined within each litter.</p>
</sec>
</sec>
<sec id="section8-1933719111424438">
<title>Results</title>
<sec id="section9-1933719111424438">
<title>In Vivo Distribution of [<sup>3</sup>H]Digoxin: Placenta</title>
<p>
<xref ref-type="fig" rid="fig1-1933719111424438">Figure 1</xref> illustrates the fetal unit to maternal plasma drug ratio for [<sup>3</sup>H]digoxin. The “fetal unit” comprises the fetus, the chorionic and amniotic membranes, and the amniotic fluid. This ratio represents the net transfer of [<sup>3</sup>H]digoxin from the maternal plasma across the placental barrier into the fetal unit. A larger ratio indicates greater net transfer of [<sup>3</sup>H]digoxin across the placenta and higher accumulation of the substrate in the fetal unit. Higher accumulation indicates reduced placental P-gp-mediated substrate efflux. There were no effects of either dose of sertraline on the accumulation of [<sup>3</sup>H]digoxin in the fetal unit at 5 minutes (<xref ref-type="fig" rid="fig1-1933719111424438">Figure 1A</xref>) and 60 minutes (<xref ref-type="fig" rid="fig1-1933719111424438">Figure 1B</xref>). However, at 240 minutes (<xref ref-type="fig" rid="fig1-1933719111424438">Figure 1C</xref>), sertraline produced a significant dose-dependent decrease in the accumulation of [<sup>3</sup>H]digoxin in the fetal unit, indicating an increase in P-gp-mediated substrate efflux in the placenta. This difference in the fetal unit to maternal plasma drug ratio resulted from significant reductions in the levels of [<sup>3</sup>H]digoxin in the fetus (<xref ref-type="fig" rid="fig1-1933719111424438">Figure 1E</xref>) with no significant change in the levels of [<sup>3</sup>H]digoxin in the maternal plasma (<xref ref-type="fig" rid="fig1-1933719111424438">Figure 1D</xref>). The latter is important as it suggests that sertraline is not affecting maternal substrate distribution/metabolism.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111424438">14</xref>
</sup>
</p>
<fig id="fig1-1933719111424438" position="float">
<label>Figure 1.</label>
<caption>
<p>Transplacental transfer of [<sup>3</sup>H]digoxin (1 μCi/30 g) to the fetal unit at (A) 5 minutes, (B) 60 minutes, and (C) 240 minutes after treatment with sertraline at 1 mg/kg (grey bar), 10 mg/kg (solid bar), or vehicle control (open bar). Values are expressed as litters averaged per dam. Bar represents mean ± standard error of the mean (SEM) drug ratio for n = 5-6 per group. Absolute levels of [<sup>3</sup>H]digoxin in the maternal plasma (D) and fetal unit (E). Values are expressed as mean DPM/100 μL maternal plasma and mean DPM/g fetal unit per group ± SEM. <italic>***P &lt; </italic>.001 versus vehicle; <italic>*P &lt; </italic>.05 versus vehicle; <sup>±±</sup>
<italic>P &lt; </italic>.01 versus 1 mg/kg.</p>
</caption>
<graphic alternate-form-of="fig1-1933719111424438" xlink:href="10.1177_1933719111424438-fig1.tif"/>
</fig>
</sec>
<sec id="section10-1933719111424438">
<title>Blood–Brain Barrier</title>
<p>
<xref ref-type="fig" rid="fig2-1933719111424438">Figure 2</xref> illustrates the fetal brain to fetal body drug ratio for [<sup>3</sup>H]digoxin. This ratio represents the net transfer of [<sup>3</sup>H]digoxin from the fetal body across the fetal BBB and into the fetal brain. A higher ratio indicates greater accumulation of [<sup>3</sup>H]digoxin in the fetal brain and reduced P-gp-mediated substrate efflux at the fetal BBB. There was no effect of either dose of sertraline on the fetal brain to fetal body ratio of [<sup>3</sup>H]digoxin at 5 minutes (<xref ref-type="fig" rid="fig2-1933719111424438">Figure 2A</xref>) and 60 minutes (<xref ref-type="fig" rid="fig2-1933719111424438">Figure 2B</xref>). However, at 240 minutes (<xref ref-type="fig" rid="fig2-1933719111424438">Figure 2C</xref>), sertraline administration resulted in a significant dose-dependent increase in the fetal brain to fetal body drug ratio of [<sup>3</sup>H]digoxin accumulation. Levels of [<sup>3</sup>H]digoxin in the fetal body (<xref ref-type="fig" rid="fig2-1933719111424438">Figure 2D</xref>) and fetal brain (<xref ref-type="fig" rid="fig2-1933719111424438">Figure 2E</xref>) are also presented. The difference in the fetal brain to fetal body drug ratio resulted primarily from significant reductions in the levels of [<sup>3</sup>H]digoxin in the fetal body. <xref ref-type="fig" rid="fig3-1933719111424438">Figure 3</xref> illustrates the maternal brain to maternal plasma drug ratio. This ratio represents the net transfer of [<sup>3</sup>H]digoxin from the maternal plasma across the BBB into the maternal brain. At 5 minutes (<xref ref-type="fig" rid="fig3-1933719111424438">Figure 3A</xref>) and 60 minutes (<xref ref-type="fig" rid="fig3-1933719111424438">Figure 3B</xref>), there were no differences in this ratio between the sertraline- and vehicle-treated groups, suggesting no effect of sertraline on P-gp-mediated substrate efflux at the maternal BBB. However, at 240 minutes (<xref ref-type="fig" rid="fig3-1933719111424438">Figure 3C</xref>), the higher dose of sertraline (10 mg/kg) produced a significant increase in [<sup>3</sup>H]digoxin accumulation in the maternal brain (<xref ref-type="fig" rid="fig3-1933719111424438">Figure 3D</xref>), suggesting an inhibitory effect of this higher dose sertraline on P-gp-mediated substrate efflux at the maternal BBB.</p>
<fig id="fig2-1933719111424438" position="float">
<label>Figure 2.</label>
<caption>
<p>Net transfer of [<sup>3</sup>H]digoxin from the fetal body to the fetal brain at (A) 5 minutes, (B) 60 minutes, and (C) 240 minutes after treatment with sertraline at 1 mg/kg (grey bar), 10 mg/kg (solid bar), or vehicle control (open bar). Values are expressed as litters averaged per dam. Bar represents mean ± standard error of the mean (SEM) drug ratio for n = 5-6 per group. Absolute levels of [<sup>3</sup>H]digoxin in the fetal body (D) and fetal brain (E). Values are expressed as mean DPM/g fetal body and mean DPM/sample fetal brain per group ± SEM. <italic>***P &lt; </italic>.001 versus vehicle, <italic>*P &lt; </italic>.05 versus vehicle; <sup>±±</sup>
<italic>P &lt; </italic>.01 versus 1 mg/kg; <sup>±</sup>
<italic>P &lt; </italic>.05 versus 1 mg/kg.</p>
</caption>
<graphic alternate-form-of="fig2-1933719111424438" xlink:href="10.1177_1933719111424438-fig2.tif"/>
</fig>
<fig id="fig3-1933719111424438" position="float">
<label>Figure 3.</label>
<caption>
<p>Net transfer of [<sup>3</sup>H]digoxin from the maternal plasma to the maternal brain at (A) 5 minutes, (B) 60 minutes, and (C) 240 minutes after treatment with sertraline at 1 mg/kg (grey bar), 10 mg/kg (solid bar), or vehicle control (open bar). Values are expressed as litters averaged per dam. Bar represents mean ± standard error of the mean (SEM) drug ratio for n = 5-6 per group. Absolute levels of [<sup>3</sup>H]digoxin in the maternal brain (D). Values are expressed as mean DPM/g maternal brain per group ± SEM. <italic>***P &lt; </italic>.001 versus vehicle; <italic>*P &lt; </italic>.05 versus vehicle; <sup>±±±</sup>
<italic>P &lt; </italic>.001 versus 1 mg/kg.</p>
</caption>
<graphic alternate-form-of="fig3-1933719111424438" xlink:href="10.1177_1933719111424438-fig3.tif"/>
</fig>
</sec>
<sec id="section11-1933719111424438">
<title>Passive Diffusion of [<sup>14</sup>C]Mannitol</title>
<p>There were no significant differences in the fetal unit to maternal plasma ratio of mannitol (vehicle [VEH]: 0.024 ± 0.006; sertraline [SER]: 0.021 ± 0.009), the fetal brain to fetal body ratio (VEH: 0.036 ± 0.017; SER: 0.064 ± 0.040), or the maternal brain to maternal plasma ratio (VEH: 0.018 ± 0.007; SER: 0.015 ± 0.008) between the sertraline- and vehicle-treated groups. This suggests that sertraline does not affect passive permeability at the placental barrier or at the BBB.</p>
</sec>
</sec>
<sec id="section12-1933719111424438">
<title>Discussion</title>
<p>In the present study, we have shown that the SSRI sertraline can influence transfer of [<sup>3</sup>H]digoxin (P-gp substrate) across the placenta and across the fetal and maternal BBB. This effect is time dependent and only occurs 240 minutes after sertraline administration. This is the first study to directly investigate the effects of an SSRI on transport of P-gp substrates in normal tissues, in vivo. Importantly, we have shown that the effects of sertraline on P-gp function appear to be tissue specific, with increased P-gp-mediated substrate efflux in the placenta and reduced P-gp-mediated substrate efflux at the fetal and maternal BBB. Furthermore, we have shown that sertraline-mediated changes in the accumulation of [<sup>3</sup>H]digoxin in the fetus and the fetal and maternal brain do not occur as a result of altered passive diffusion at these blood–barrier sites.</p>
<p>It has been demonstrated that the SSRI fluoxetine meets all 3 in vitro criteria for being a P-gp inhibitor: drug efflux, drug accumulation, and cytotoxicity.<sup>
<xref ref-type="bibr" rid="bibr30-1933719111424438">30</xref>
</sup> Specifically, fluoxetine slowed drug efflux (70%) and increased cellular accumulation of drugs (32%), resulting in increased cytoxocity (10-fold) of the anticancer drug, and P-gp substrate, doxorubicin.<sup>
<xref ref-type="bibr" rid="bibr19-1933719111424438">19</xref>
</sup> The potency of fluoxetine as a P-gp inhibitor was comparable with the potency of other P-gp inhibitors, verapamil and cyclosporin A, in vitro.<sup>
<xref ref-type="bibr" rid="bibr30-1933719111424438">30</xref>
</sup> Oral administration of fluoxetine has been shown to produce a significant increase in doxorubicin accumulation in lung tumors, slow down tumor progression, and increase survival by 2 to 3-fold, in vivo.<sup>
<xref ref-type="bibr" rid="bibr30-1933719111424438">30</xref>
</sup> In the present study, sertraline was selected over fluoxetine because it has been shown to be a more potent P-gp inhibitor in other cell systems.<sup>
<xref ref-type="bibr" rid="bibr17-1933719111424438">17</xref>
</sup> In L-MDR1 cells (which overexpress the human P-gp) and porcine brain capillary endothelial cells, the SSRIs sertraline, desmethylsertraline, and paroxetine inhibit the activity of P-gp to a degree that is comparable to the established P-gp inhibitor verapamil.<sup>
<xref ref-type="bibr" rid="bibr17-1933719111424438">17</xref>
</sup> The advantage of SSRIs over other known P-gp inhibitors is that they do not appear to alter drug metabolism or distribution, in vivo.<sup>
<xref ref-type="bibr" rid="bibr31-1933719111424438">31</xref>
</sup> In the present study, sertraline did not significantly affect levels of [<sup>3</sup>H]digoxin in the maternal circulation at any time point, confirming these previous observations.</p>
<p>While the SSRIs have been shown to inhibit P-gp function in tumor cells, the present study is the first to demonstrate that an SSRI may have tissue-specific effects on P-gp function in normal tissues, in vivo. In the fetal and maternal BBB, sertraline appears to exert an inhibitory effect on P-gp resulting in increased substrate transfer into the brain. This is consistent with the inhibitory effects that have been reported in tumor and normal cell lines, in vitro.<sup>
<xref ref-type="bibr" rid="bibr17-1933719111424438">17</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr19-1933719111424438">19</xref>,<xref ref-type="bibr" rid="bibr30-1933719111424438">30</xref>
</sup> In the fetus, the reduction in the fetal brain to fetal body digoxin ratio caused by sertraline is primarily a result of a reduction in fetal body levels of [<sup>3</sup>H]digoxin with only modest increases in absolute levels of digoxin in the fetal brain. It is also interesting to note that the fetal brain:fetal body ratio of digoxin is lower at 240 minutes than at either 5 or 60 minutes. Given that the activity of P-gp has been shown to increase in response to increased presence of substrate,<sup>
<xref ref-type="bibr" rid="bibr21-1933719111424438">21</xref>
</sup> it is quite possible that the activity of P-gp at the fetal BBB increases as a result of increasing digoxin concentrations in the fetal circulation. Future studies are required to probe this possibility in greater detail.</p>
<p>In contrast to the situation at the fetal BBB, in the placenta, sertraline reduced net transfer of P-gp substrate from the maternal circulation to the fetal unit, suggesting that the SSRIs increase P-gp-mediated substrate efflux in the placenta, enhancing the ability of the placenta to prevent xenobiotics from entering the fetus. Previous studies have shown that the same drug can have different effects on P-gp function in different tissues.<sup>
<xref ref-type="bibr" rid="bibr32-1933719111424438">32</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr33-1933719111424438">33</xref>
</sup> For example, rifampin has been shown to increase intestinal accumulation of digoxin but have no effect on accumulation of digoxin in the kidneys.<sup>
<xref ref-type="bibr" rid="bibr32-1933719111424438">32</xref>
</sup> In another study, adjuvant arthritic rats showed decreased activity of P-gp in the liver, but no difference in the activity of P-gp in the intestines was observed when compared with normal rats.<sup>
<xref ref-type="bibr" rid="bibr33-1933719111424438">33</xref>
</sup> The authors concluded that different regulation systems might be involved in the liver and intestine.</p>
<p>The mechanism for SSRI-induced inhibition of P-gp function is not known. Uhr and colleagues showed that doxepin, venlafaxine, and paroxetine concentrations in the cerebrum were higher in <italic>Abcb1ab</italic> knockout mice, suggesting that SSRIs may be P-gp substrates.<sup>
<xref ref-type="bibr" rid="bibr34-1933719111424438">34</xref>
</sup> If this is the case, then SSRIs may effectively inhibit P-gp-mediated substrate efflux by competing with other substrates for access to the drug-binding site making them competitive inhibitors of P-gp substrates. If the SSRIs are P-gp substrates, it may seem to counterintuitive that sertraline is stimulating P-gp-mediated digoxin transfer in the placenta. However, previous studies have shown that 1 P-gp substrate can increase P-gp-mediated transport of another substrate.<sup>
<xref ref-type="bibr" rid="bibr35-1933719111424438">35</xref>
</sup> Shapiro and Ling showed this in plasma membrane vesicles of the hamster ovary.<sup>
<xref ref-type="bibr" rid="bibr35-1933719111424438">35</xref>
</sup> They concluded that their findings are most likely explained by the presence of 2 transport-competent drug-binding sites, the H site and the R site, that interact in a positively cooperative manner.<sup>
<xref ref-type="bibr" rid="bibr35-1933719111424438">35</xref>
</sup> Studies have shown that the H and R sites not only bind and transport specific substrates but also can have overlapping specificities.<sup>
<xref ref-type="bibr" rid="bibr35-1933719111424438">35</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr36-1933719111424438">36</xref>
</sup> Consequently, it is possible that sertraline and digoxin interact with distinct drug-binding sites on placental P-gp. For instance, if sertraline binds to the H site and digoxin binds to the R site on placental P-gp, then these 2 drugs may stimulate transport of one another in a positive cooperative manner. In addition, other studies have shown that some compounds can modulate P-gp by binding to sites distinct from the drug-binding site. For example, some steroid modulators bind to a high-affinity site within NBD1 domain that is close to the ATP-binding site.<sup>
<xref ref-type="bibr" rid="bibr37-1933719111424438">37</xref>
</sup> Fitting into the Shapiro–Ling model, it is possible that while sertraline competes with digoxin for access to the same drug-binding site on BBB P-gp, sertraline and digoxin bind to 2 distinct drug-binding sites on placental P-gp. Further studies are required to determine the mechanisms by which SSRIs interact with P-gp drug-binding sites and consequently influence the transport of other substrates in both normal and cancer cells.</p>
<p>Tissue-specific effects of the SSRI sertraline on P-gp-mediated drug transport may also result from unique functional properties of the predominant P-gp isoforms found in the placental syncytiotrophoblast and in the endothelial cells of the brain microvasculature.<sup>
<xref ref-type="bibr" rid="bibr3-1933719111424438">3</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr4-1933719111424438">4</xref>
</sup> In the mouse, 2 genes encode P-gp: <italic>Abcb1a</italic> and <italic>Abcb1b</italic>. While the P-gp protein isoforms encoded by these genes share 84% amino acid identity, they are differentially expressed in the body.<sup>
<xref ref-type="bibr" rid="bibr38-1933719111424438">38</xref>
</sup> The P-gp encoded by <italic>Abcb1a</italic> predominates in the intestine, liver, lung, and blood–brain barrier,<sup>
<xref ref-type="bibr" rid="bibr12-1933719111424438">12</xref>
</sup> whereas P-gp encoded by <italic>Abcb1b</italic> predominates in tissues associated with steroid biosynthesis and distribution, such as the adrenal, ovary, and placenta.<sup>
<xref ref-type="bibr" rid="bibr39-1933719111424438">39</xref>
</sup> In addition to differences in localization, there have been reported differences in the biochemical properties of P-gp encoded by <italic>Abcb1a</italic> and <italic>Abcb1b</italic>. One of the studies showed that progesterone could distinguish the transport properties of the 2 P-gp isoforms.<sup>
<xref ref-type="bibr" rid="bibr40-1933719111424438">40</xref>
</sup> Progesterone was used to show that the <italic>Abcb1a</italic>-encoded P-gp was a more efficient efflux pump than the <italic>Abcb1b</italic>-encoded P-gp. This study also found a single class of vinblastine-binding sites on <italic>Abcb1b</italic>-encoded P-gp and 2 classes of such sites on the <italic>Abcb1a</italic>-encoded P-gp. There have also been reports that the 2 P-gp isoforms differ in their ability to confer cellular resistance to drugs, including colchicine and actinomycin D, in vitro.<sup>
<xref ref-type="bibr" rid="bibr40-1933719111424438">40</xref>
<xref ref-type="bibr" rid="bibr41-1933719111424438"/>
<xref ref-type="bibr" rid="bibr42-1933719111424438"/>–<xref ref-type="bibr" rid="bibr43-1933719111424438">43</xref>
</sup> However, these earlier studies used indirect tests to assess substrate specificity and their significance has been questioned by more recent studies, which have reported no difference in the affinity of the 2 isoforms toward vinblastine.<sup>
<xref ref-type="bibr" rid="bibr38-1933719111424438">38</xref>
</sup> It was concluded in these more recent studies that if any difference in transport exists between the 2 P-gp isoforms, it must occur at a step subsequent to binding, such as the translocation step or linkage between drug binding and ATP hydrolysis.<sup>
<xref ref-type="bibr" rid="bibr38-1933719111424438">38</xref>
</sup> It is possible that sertraline can differentially affect the expression of <italic>Abcb1a</italic> and <italic>Abcb1b</italic> in the placenta and BBB. With respect to the results obtained in the present experiment, sertraline may be increasing the expression of placental <italic>Abcb1a</italic> and <italic>Abcb1b</italic> at 240 minutes, resulting in increased activity of P-gp and reduced [<sup>3</sup>H]digoxin accumulation in the fetal unit. At the same time, sertraline may decrease the expression of <italic>Abcb1a</italic> and <italic>Abc1b</italic> at the BBB, thereby increasing [<sup>3</sup>H]digoxin accumulation in the brain. It is also possible that sertraline may alter the ratio of <italic>Abcb1a</italic> and <italic>Abcb1b</italic> at these barrier sites. However, to date, there have been no reports of SSRIs affecting the expression of <italic>Abcb1a</italic> or <italic>Abcb1b</italic>. Another possible explanation for the fact that sertraline can exhibit both inhibitory and stimulatory effects may relate to local tissue concentrations of sertraline. However, the fact that sertraline inhibited the activity of P-gp at both the fetal and maternal BBB does not really support such an explanation. Clearly, further studies are required to investigate the novel tissue-specific nature of the effects of sertraline on P-gp function.</p>
<p>The fact that acute SSRI treatment increases P-gp substrate accumulation in the fetal brain may contribute to many of the neonatal complications associated with chronic prenatal SSRI exposure.<sup>
<xref ref-type="bibr" rid="bibr44-1933719111424438">44</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr45-1933719111424438">45</xref>
</sup> The prevalence of mood disorders during pregnancy is estimated to be 10% to 15%.<sup>
<xref ref-type="bibr" rid="bibr20-1933719111424438">20</xref>
</sup> Many of these women are treated with SSRIs, including sertraline.<sup>
<xref ref-type="bibr" rid="bibr20-1933719111424438">20</xref>
</sup> Chronic prenatal exposure to SSRIs has been associated with significant increases in the rate of neonatal behavioral syndrome that includes irritability, prolonged crying, tremors, seizures, and difficulty feeding and sleeping.<sup>
<xref ref-type="bibr" rid="bibr45-1933719111424438">45</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr46-1933719111424438">46</xref>
</sup> In addition, there have been reported deficits in cognitive ability in neonates that are prenatally exposed to SSRI.<sup>
<xref ref-type="bibr" rid="bibr47-1933719111424438">47</xref>
</sup> Chronic maternal SSRI treatment during pregnancy has also been shown to produce an attenuated adrenocorticotropic hormone and cortisol response in rats and humans.<sup>
<xref ref-type="bibr" rid="bibr48-1933719111424438">48</xref>
</sup>
<sup>,<xref ref-type="bibr" rid="bibr49-1933719111424438">49</xref>
</sup> It is possible that these neurodevelopmental effects result, in part, from the effects that SSRIs are having on substrate transport at the fetal BBB. If chronic SSRI treatment maintains the inhibition of P-gp-mediated substrate efflux at the fetal BBB, this could allow for increased accumulation of xenobiotics, as well as other endogenous substrates, that are normally excluded from the fetal brain by P-gp.</p>
<p>In conclusion, sertraline influences transfer of P-gp substrates across the placenta and across the fetal and maternal BBB. This effect is dose and time dependent, only occurring at 240 minutes after sertraline administration. Importantly, we are the first to show that the effects of an SSRI on P-gp function could be tissue specific, with sertraline increasing P-gp-mediated substrate efflux in the placenta and reducing P-gp-mediated substrate efflux at the fetal and maternal BBB. Given the widespread use of SSRIs during human pregnancy, our present findings have important clinical implications. Furthermore, improving our understanding of the actions of SSRIs on P-gp function, and therefore fetal protection, may allow development of novel modalities of drug therapy during pregnancy.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1933719111424438">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1933719111424438">
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: supported by funding from the Canadian Institutes for Health Research ([CIHR]; FRN-84220) to SGM and WG and CIHR Graduate Studentships to MB and SP.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1933719111424438">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juliano</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants</article-title>. <source>Biochim Biophys Acta</source>. <year>1976</year>;<volume>455</volume>(<issue>1</issue>):<fpage>152</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr2-1933719111424438">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thiebaut</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tsuruo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hamada</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gottesman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Pastan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Willingham</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>1987</year>;<volume>84</volume>(<issue>21</issue>):<fpage>7735</fpage>–<lpage>7738</lpage>.</citation>
</ref>
<ref id="bibr3-1933719111424438">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croop</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haber</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues</article-title>. <source>Mol Cell Biol</source>. <year>1989</year>;<volume>9</volume>(<issue>3</issue>):<fpage>1346</fpage>–<lpage>1350</lpage>.</citation>
</ref>
<ref id="bibr4-1933719111424438">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottesman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Pastan</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Biochemistry of multidrug resistance mediated by the multidrug transporter</article-title>. <source>Annu Rev Biochem</source>. <year>1993</year>;<volume>62</volume>:<fpage>385</fpage>–<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr5-1933719111424438">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacFarland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abramovich</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Ewen</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>CK</given-names>
</name>
</person-group>. <article-title>Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta</article-title>. <source>J Histochem</source>. <year>1994</year>;<volume>26</volume>(<issue>5</issue>):<fpage>417</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr6-1933719111424438">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kingdom</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baczyk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lye</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation</article-title>. <source>Placenta</source>. <year>2006</year>;<volume>27</volume>(<issue>6-7</issue>):<fpage>602</fpage>–<lpage>609</lpage>.</citation>
</ref>
<ref id="bibr7-1933719111424438">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalabis</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Kostaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Petropoulos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection</article-title>. <source>Biol Reprod</source>. <year>2005</year>;<volume>73</volume>(<issue>4</issue>):<fpage>591</fpage>–<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr8-1933719111424438">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mylona</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hoyland</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Sibley</surname>
<given-names>CP</given-names>
</name>
</person-group>. <article-title>Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: no evidence for complementary expression</article-title>. <source>Placenta</source>. <year>1999</year>;<volume>20</volume>(<issue>5-6</issue>):<fpage>493</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr9-1933719111424438">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier</article-title>. <source>Endocrinology</source>. <year>2011</year>;<volume>152</volume>(<issue>3</issue>):<fpage>1067</fpage>–<lpage>1079</lpage>.</citation>
</ref>
<ref id="bibr10-1933719111424438">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Kalken</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Giaccone</surname>
<given-names>G</given-names>
</name>
<name>
<surname>van der Valk</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Multidrug resistance gene (P-glycoprotein) expression in the human fetus</article-title>. <source>Am J Pathol</source>. <year>1992</year>;<volume>141</volume>(<issue>5</issue>):<fpage>1063</fpage>–<lpage>1072</lpage>.</citation>
</ref>
<ref id="bibr11-1933719111424438">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ueda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone</article-title>. <source>J Biol Chem</source>. <year>1992</year>;<volume>267</volume>(<issue>34</issue>):<fpage>24248</fpage>–<lpage>24252</lpage>.</citation>
</ref>
<ref id="bibr12-1933719111424438">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schinkel</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>van Tellingen</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group> <article-title>Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs</article-title>. <source>Cell</source>. <year>1994</year>;<volume>77</volume>(<issue>4</issue>):<fpage>491</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr13-1933719111424438">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schinkel</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Wagenaar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>van Deemter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mol</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Borst</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A</article-title>. <source>J Clin Invest</source>. <year>1995</year>;<volume>96</volume>(<issue>4</issue>):<fpage>1698</fpage>–<lpage>1705</lpage>.</citation>
</ref>
<ref id="bibr14-1933719111424438">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smit</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Huisman</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>van Tellingen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Wiltshire</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Schinkel</surname>
<given-names>AH</given-names>
</name>
</person-group>. <article-title>Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure</article-title>. <source>J Clin Invest</source>. <year>1999</year>;<volume>104</volume>(<issue>10</issue>):<fpage>1441</fpage>–<lpage>1447</lpage>.</citation>
</ref>
<ref id="bibr15-1933719111424438">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schinkel</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Jonker</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview</article-title>. <source>Adv Drug Deliv Rev</source>. <year>2003</year>;<volume>55</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr16-1933719111424438">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ambudkar</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Kimchi-Sarfaty</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sauna</surname>
<given-names>ZE</given-names>
</name>
<name>
<surname>Gottesman</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>P-glycoprotein: from genomics to mechanism</article-title>. <source>Oncogene</source>. <year>2003</year>;<volume>22</volume>(<issue>47</issue>):<fpage>7468</fpage>–<lpage>7485</lpage>.</citation>
</ref>
<ref id="bibr17-1933719111424438">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dormann</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Martin-Facklam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kerpen</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Ketabi-Kiyanvash</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Haefeli</surname>
<given-names>WE</given-names>
</name>
</person-group>. <article-title>Inhibition of P-glycoprotein by newer antidepressants</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2003</year>;<volume>305</volume>(<issue>1</issue>):<fpage>197</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr18-1933719111424438">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dekel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Melikhov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Margalit</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>(<issue>20</issue>):<fpage>7562</fpage>–<lpage>7569</lpage>.</citation>
</ref>
<ref id="bibr19-1933719111424438">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kashi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Peer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Margalit</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen</article-title>. <source>Cancer Lett</source>. <year>2009</year>;<volume>274</volume>(<issue>1</issue>):<fpage>118</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr20-1933719111424438">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Heron</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Francomb</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oke</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Golding</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Cohort study of depressed mood during pregnancy and after childbirth</article-title>. <source>BMJ</source>. <year>2001</year>;<volume>323</volume>(<issue>7307</issue>):<fpage>257</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr21-1933719111424438">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petropoulos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kalabis</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>Functional changes of mouse placental multidrug resistance phosphoglycoprotein (ABCB1) with advancing gestation and regulation by progesterone</article-title>. <source>Reprod Sci</source>. <year>2007</year>;<volume>14</volume>(<issue>4</issue>):<fpage>321</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr22-1933719111424438">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petropoulos</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gibb</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation</article-title>. <source>Brain Res</source>. <year>2010</year>;<volume>1357</volume>:<fpage>9</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr23-1933719111424438">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marken</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Munro</surname>
<given-names>JS</given-names>
</name>
</person-group>. <article-title>Selecting a selective serotonin re</article-title>uptake inhibitor: clinically important distinguishing features. <source>Prim Care Companion J Clin Psychiatry</source>. <year>2000</year>;<volume>2</volume>(<issue>6</issue>):<fpage>205</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr24-1933719111424438">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayer</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Wagenaar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dorobek</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Beijnen</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Borst</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schinkel</surname>
<given-names>AH</given-names>
</name>
</person-group>. <article-title>Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833</article-title>. <source>J Clin Invest</source>. <year>1997</year>;<volume>100</volume>(<issue>10</issue>):<fpage>2430</fpage>–<lpage>2436</lpage>.</citation>
</ref>
<ref id="bibr25-1933719111424438">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fenner</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Troutman</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Kempshall</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug</article-title>. <source>Clin Pharmacol Ther</source>. <year>2009</year>;<volume>85</volume>(<issue>2</issue>):<fpage>173</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr26-1933719111424438">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bond</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group> <article-title>Artificial perfusion of the fetal circulation of the in situ mouse placenta: methodology and validation</article-title>. <source>Placenta</source>. <year>2006</year>;<volume>27</volume>(<issue>suppl A</issue>):<fpage>S69</fpage>–<lpage>S75</lpage>.</citation>
</ref>
<ref id="bibr27-1933719111424438">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coles</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Eddington</surname>
<given-names>ND</given-names>
</name>
</person-group>. <article-title>Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice</article-title>. <source>J Pharm Sci</source>. <year>2009</year>;<volume>98</volume>(<issue>8</issue>):<fpage>2832</fpage>–<lpage>2846</lpage>.</citation>
</ref>
<ref id="bibr28-1933719111424438">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sibley</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Coan</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Ferguson-Smith</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group> <article-title>Placental-specific insulin-like growth factor 2 (Igf2) regulates the diffusional exchange characteristics of the mouse placenta</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2004</year>;<volume>101</volume>(<issue>21</issue>):<fpage>8204</fpage>–<lpage>8208</lpage>.</citation>
</ref>
<ref id="bibr29-1933719111424438">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McClive</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Sinclair</surname>
<given-names>AH</given-names>
</name>
</person-group>. <article-title>Rapid DNA extraction and PCR-sexing of mouse embryos</article-title>. <source>Mol Reprod Dev</source>. <year>2001</year>;<volume>60</volume>(<issue>2</issue>):<fpage>225</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr30-1933719111424438">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Margalit</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Fluoxetine and reversal of multidrug resistance</article-title>. <source>Cancer Lett</source>. <year>2006</year>;<volume>237</volume>(<issue>2</issue>):<fpage>180</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr31-1933719111424438">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ereshefsky</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Drug-drug interactions involving antidepressants: focus on venlafaxine</article-title>. <source>J Clin Psychopharmacol</source>. <year>1996</year>;<volume>16</volume>(<issue>3 suppl 2</issue>):<fpage>37S</fpage>–<lpage>50S</lpage>; <comment>discussion 50S-53S</comment>.</citation>
</ref>
<ref id="bibr32-1933719111424438">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greiner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eichelbaum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</article-title>. <source>J Clin Invest</source>. <year>1999</year>;<volume>104</volume>(<issue>2</issue>):<fpage>147</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr33-1933719111424438">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Achira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Totsuka</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fujimura</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kume</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats</article-title>. <source>Eur J Pharm Sci</source>. <year>2002</year>;<volume>16</volume>(<issue>1-2</issue>):<fpage>29</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr34-1933719111424438">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uhr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grauer</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption</article-title>. <source>Biol Psychiatry</source>. <year>2003</year>;<volume>54</volume>(<issue>8</issue>):<fpage>840</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr35-1933719111424438">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities</article-title>. <source>Eur J Biochem</source>. <year>1997</year>;<volume>250</volume>(<issue>1</issue>):<fpage>130</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr36-1933719111424438">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sterz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mollmann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Baumert</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wiese</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Activators of P-glycoprotein: s</article-title>tructure-activity relationships and investigation of their mode of action. <source>Chem Med Chem</source>. <year>2009</year>;<volume>4</volume>(<issue>11</issue>):<fpage>1897</fpage>–<lpage>1911</lpage>.</citation>
</ref>
<ref id="bibr37-1933719111424438">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dayan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jault</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Baubichon-Cortay</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site</article-title>. <source>Biochemistry</source>. <year>1997</year>;<volume>36</volume>(<issue>49</issue>):<fpage>15208</fpage>–<lpage>15215</lpage>.</citation>
</ref>
<ref id="bibr38-1933719111424438">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ferry</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Callaghan</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar</article-title>. <source>Br J Cancer</source>. <year>1999</year>;<volume>81</volume>(<issue>5</issue>):<fpage>783</fpage>–<lpage>789</lpage>.</citation>
</ref>
<ref id="bibr39-1933719111424438">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trezise</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>DR</given-names>
</name>
<etal/>
</person-group> <article-title>The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression</article-title>. <source>J EMBO</source>. <year>1992</year>;<volume>11</volume>(<issue>12</issue>):<fpage>4291</fpage>–<lpage>4303</lpage>.</citation>
</ref>
<ref id="bibr40-1933719111424438">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Greenberger</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Horwitz</surname>
<given-names>SB</given-names>
</name>
</person-group>. <article-title>Differential transport properties of two mdr gene products are distinguished by progesterone</article-title>. <source>J Biol Chem</source>. <year>1990</year>;<volume>265</volume>(<issue>18</issue>):<fpage>10282</fpage>–<lpage>10288</lpage>.</citation>
</ref>
<ref id="bibr41-1933719111424438">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devault</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gros</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities</article-title>. <source>Mol Cell Biol</source>. <year>1990</year>;<volume>10</volume>(<issue>4</issue>):<fpage>1652</fpage>–<lpage>1663</lpage>.</citation>
</ref>
<ref id="bibr42-1933719111424438">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kajiji</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Talbot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Grizzuti</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site</article-title>. <source>Biochemistry</source>. <year>1993</year>;<volume>32</volume>(<issue>16</issue>):<fpage>4185</fpage>–<lpage>4194</lpage>.</citation>
</ref>
<ref id="bibr43-1933719111424438">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang-Wai</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Kajiji</surname>
<given-names>S</given-names>
</name>
<name>
<surname>DiCapua</surname>
<given-names>F</given-names>
</name>
<name>
<surname>de Graaf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Roninson</surname>
<given-names>IB</given-names>
</name>
<name>
<surname>Gros</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators</article-title>. <source>Biochemistry</source>. <year>1995</year>;<volume>34</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr44-1933719111424438">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De las Cuevas</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sanz</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Safety of selective serotonin reuptake inhibitors in pregnancy</article-title>. <source>Curr Drug Saf</source>. <year>2006</year>;<volume>1</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr45-1933719111424438">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuccori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Testi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Antonioli</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review</article-title>. <source>Clin Ther</source>. <year>2009</year>;<volume>31</volume>(<issue>pt 1</issue>):<fpage>1426</fpage>–<lpage>1453</lpage>.</citation>
</ref>
<ref id="bibr46-1933719111424438">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moses-Kolko</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Bogen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Perel</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>293</volume>(<issue>19</issue>):<fpage>2372</fpage>–<lpage>2383</lpage>.</citation>
</ref>
<ref id="bibr47-1933719111424438">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casper</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Fleisher</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Lee-Ancajas</surname>
<given-names>JC</given-names>
</name>
<etal/>
</person-group> <article-title>Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy</article-title>. <source>J Pediatr</source>. <year>2003</year>;<volume>142</volume>(<issue>4</issue>):<fpage>402</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr48-1933719111424438">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berlin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Warot</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Legout</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Guillemant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schollnhammer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Puech</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects</article-title>. <source>Clin Pharmacol Ther</source>. <year>1998</year>;<volume>63</volume>(<issue>4</issue>):<fpage>428</fpage>–<lpage>436</lpage>.</citation>
</ref>
<ref id="bibr49-1933719111424438">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raap</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group> <article-title>Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1999</year>;<volume>288</volume>(<issue>1</issue>):<fpage>98</fpage>–<lpage>106</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>